Regorafenib with a fluoropyrimidine for metastatic colorectal cancer after progression on multiple 5-FU-containing combination therapies and regorafenib monotherapy

Cancer statistics, 2015

(2015) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: A phase II trial

(2015) Guillem Argilés et al.   EUROPEAN JOURNAL OF CANCER

Regorafenib Inhibits Colorectal Tumor Growth through PUMA-Mediated Apoptosis

(2014) D. Chen et al.   CLINICAL CANCER RESEARCH

Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study

(2013) B. Schultheis et al.   ANNALS OF ONCOLOGY

Options for metastatic colorectal cancer beyond the second line of treatment

(2013) Fanny Foubert et al.   DIGESTIVE AND LIVER DISEASE

Regorafenib: A Review of Its Use in Previously Treated Patients with Progressive Metastatic Colorectal Cancer

(2013) Natalie J. Carter   DRUGS & AGING

Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study

(2012) D Strumberg et al.   BRITISH JOURNAL OF CANCER

A Phase I Dose-Escalation Study of Regorafenib (BAY 73-4506), an Inhibitor of Oncogenic, Angiogenic, and Stromal Kinases, in Patients with Advanced Solid Tumors

(2012) K. Mross et al.   CLINICAL CANCER RESEARCH

Fluoro-Sorafenib (Regorafenib) effects on hepatoma cells: Growth inhibition, quiescence, and recovery

(2012) Brian I. Carr et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

(2012) Axel Grothey et al.   LANCET

Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity

(2010) Scott M. Wilhelm et al.   INTERNATIONAL JOURNAL OF CANCER